NCT03772132

Chemothetapy FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

A Multicentre, Open-label, Randomised, Controlled Study of Molecularly Precision Target Therapy Based on Tumor Molecular Profiling With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Shanghai Jiao Tong University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the feasibility, efficacy and safety of FORFIRINOX in advanced or recurrent extrahepatic cholangiocarcinoma and gallbladder carcinoma.

Detailed description

The purpose of this study is to evaluate the feasibility, efficacy and safety of FORFIRINOX in advanced or recurrent extrahepatic cholangiocarcinoma and gallbladder carcinoma.

Conditions

• Cholangiocarcinoma of the Extrahepatic Bile Duct
• Gallbladder Cancer

Interventions

Type	Name	Description
BIOLOGICAL	mutation and signal pathway activation status analysis Drug: FORFIRINOX	Conventional chemotherapy:5FU plus irinote- can plus oxaliplatin combination therapy

Timeline

• Start date: 2016-07-01
• Primary completion: 2020-12-01
• Completion: 2021-12-01
• First posted: 2018-12-11
• Last updated: 2018-12-11

Locations

1 site across 1 country: China